China Pharma Subsidiary Helpson Acquires Ipragliflozin Patent For $9.8M Paid In Common Stock At $1.40/Share

On December 22, 2025, Hainan Helpson Medical & Biotechnology Co., Ltd ("Helpson"), a wholly owned subsidiary of China Pharma Holdings, Inc. (the "Company"), entered into a Technology Transfer Agreement (the "Agreement") with Juan Zhang (the "Transferor"). The Transferor owns an invention patent of an Ipragliflozin tablets and Method for Its Preparation (the "Invention Patent"). Pursuant to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide relevant technical services, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services.

 

The transfer price as contemplated by the Agreement is $9.8 million, which will be paid in the form of common stock of the Company, par value $0.001 per share (the "Common Stock"), at $1.40 per share.